Skip to content
Thursday 13 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,757.90
-0.69%
DAX
26,292.00
-0.15%
CAC 40
8,649.89
-0.29%
STOXX 50
6,544.28
+0.16%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sunday 07 February 2021 4:13 pm  |  Updated:  Sunday 07 February 2021 6:39 pm

More than 12 million have had first dose of Covid vaccine

By: Hannah Godfrey

Add as a preferred source on Google
Astrazeneca Pfizer vaccines

More than 12 million people have had the first dose of a vaccine against Covid-19, the Department of Health and Social Care announced today.

As of today, some 12,014,288 people have had a first dose of a vaccine against coronavirus.

More than half a million individuals have had a second dose of a coronavirus vaccine, giving them greater defence against the virus.

Meanwhile the latest Covid-19 data showed a further 15,845 people had tested positive for the virus, and another 373 have died within 28 days of a positive test.

This morning vaccine minister Nadhim Zahawi said a Covid-19 booster in the autumn and then annual vaccinations were very probable.

“We see very much probably an annual or a booster in the autumn and then an annual (vaccination), in the way we do with flu vaccinations where you look at what variant of virus is spreading around the world,” Zahawi told the Andrew Marr Show.

Vaccine targets

The government is on target to deliver vaccines to the 13.9 million people most vulnerable to Covid-19 by mid-February.

A senior government adviser said all adults over the age of 50 will receive a vaccine by May.

The timeline means more than 32m people will have been offered a first dose of the vaccine by the summer — almost half the UK population.

The news comes as an AstraZeneca study found its vaccine, which it developed in partnership with the University of Oxford, had significantly reduced efficacy against the South African variant.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • Revolut takes flight with launch of new airport lounges

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

    Business Wire
  • IGI Reports Second Quarter and First Six Months of 2026 Unaudited Financial Results and Declares Ordinary Common Share Dividend

    Business Wire
  • Reply S.p.A: The Board of Directors Approves the Half-year Financial Report as of 30 June 2026

    Business Wire
  • Bregal Milestone III Closes at its Increased Hard Cap of €915 Million

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook